NCT04509596 2025-04-01DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast CancerDizal PharmaceuticalsPhase 1 Completed23 enrolled
NCT01876251 2019-03-15A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast CancerPfizerPhase 1 Terminated30 enrolled 29 charts